natgillin/translations-raw huggingface dataset:
Tacrolimus (5 mg single dose)/ sofosbuvir (400 mg single dose)h 
sofosbuvir (400 mg enkratni odmerek)h
↔ Cmin 1.08 (0.98, 1.20) Ritonavir ↔ Cmax 1.17 (1.01, 1.35) 
↔ Cmin 1,08 (0,98; 1,20) Ritonavir
GS-331007 ↑ Cmax 1.33 (1.22, 1.44) 
↑ Cmax 1,33 (1,22; 1,44)
Skin and subcutaneous tissue disorders: Common rash 
Bolezni kože in podkožja:
↔ Cmin 1.07 (1.02, 1.13) 
↔ Cmax 1,14 (1,01; 1,29)
STATEMENT OF ACTIVE SUBSTANCE(S) 
(vzdrževalna terapija z metadonom [30 do
Darunavir boosted with ritonavir (800 mg/ 100 mg once daily)/ sofosbuvir (400 mg once daily) 
(800 mg/ 100 mg enkrat na dan)/ sofosbuvir (400 mg enkrat na dan)
Ledipasvir ↓ Cmax 0.89 (0.61, 1.30) 
↓ Cmax 0,89 (0,61; 1,30) ↓ AUC 0,96 (0,66; 1,39)
Treatment-naïve Patients without cirrhosis 100% (20/20) Patients with cirrhosis Treatment-experienced 
Predhodno nezdravljeni Bolniki brez ciroze Bolniki s cirozo Predhodno zdravljeni
used to treat HIV infection; 
PROTIVIRUSNA ZDRAVILA PROTI HIV: ZAVIRALCI PROTEAZE HIV
Ledipasvir ↓ Cmax 0.65 (0.56, 0.76) 
↓ Cmax 0,66 (0,59; 0,75) ↓ AUC 0,66 (0,59; 0,75) ↓ Cmin 0,66 (0,57; 0,76)
GS-331007 ↔ Cmax 1.06 (1.01, 1.11) 
GS-331007 ↔ Cmax 1,06 (1,01; 1,11) ↔ AUC 1,15 (1,11; 1,19)
Moderate RI 
Zmerna ledvična okvara
Ledipasvir ↓ Cmax 0.80 (0.69, 0.93) 
↓ Cmax 0,80 (0,69; 0,93) ↔ AUC 0,89 (0,76; 1,06)
↔ Cmin 1.06 (0.97, 1.15) Rilpivirine ↔ Cmax 0.97 (0.88, 1.07) 
↔ Cmax 1,02 (0,98; 1,06) ↔ AUC 1,05 (1,02; 1,08) ↔ Cmin 1,06 (0,97; 1,15)
GS-331007 ↔ Cmax 0.97 (0.83, 1.14) 
GS-331007 ↓ Cmax 0,73 (0,65; 0,83) ↔ AUC 1,04 (0,89; 1,22)
↑ Cmin 1.36 (1.23, 1.49) Cobicistat ↔ Cmax 1.25 (1.18, 1.32) 
↔ Cmax 1,25 (1,18; 1,32) ↑ AUC 1,59 (1,49; 1,70) ↑ Cmin 4,25 (3,47; 5,22)
Abacavir ↔ Cmax 0.92 (0.87, 0.97) 
↔ Cmax 0,92 (0,87; 0,97) ↔ AUC 0,90 (0,85; 0,94)
↑ Cmin 1.91 (1.74, 2.10) Ledipasvir ↔ Cmax 1.01 (0.95, 1.07) 
↑ Cmax 1,68 (1,54; 1,84) ↑ AUC 1,96 (1,74; 2,21) ↑ Cmin 2,18 (1,91; 2,50)
No dose adjustment of Harvoni or efavirenz/ emtricitabine/ tenofovir disoproxil fumarate is required. 
Odmerka zdravila Harvoni ali emtricitabina/
↔ Cmin 1.28 (1.21, 1.36) 
↔ Cmax 1,23 (1,14; 1,34)
FCH 
PC
↑ Ritonavir 
Jetrna okvara
↑ Cmin 1.47 (1.38, 1.57) Ledipasvir ↑ Cmax 1.68 (1.54, 1.84) 
↑ Cmax 1,47 (1,37; 1,58) ↔ AUC 1,35 (1,29; 1,42) ↑ Cmin 1,47 (1,38; 1,57)
Cirrhosis 
Cirozad
↔ Cmin 0.95 (0.74, 1.22) Sofosbuvir ↓ Cmax 0.95 (0.68, 1.33) 
↔ Cmax 0,95 (0,87; 1,04) ↔ AUC 0,89 (0,84; 0,95) (indukcija CYP3A)
LDV/SOF+RBV 24 weeks (n = 307)a,b 
LDV/SOF+RBV 24 tednov (n = 111)
↓ Cmin 0.66 (0.57, 0.76) Sofosbuvir ↔ Cmax 1.03 (0.87, 1.23) 
↓ Cmax 0,65 (0,56; 0,76) ↓ AUC 0,41 (0,36; 0,48)
These measures will help to protect the environment . 
Taki ukrepi pomagajo varovati okolje.
These effects usually do not last longer than 30 minutes. 
Ti učinki običajno ne trajajo dlje kot 30 minut.
Date of first authorisation: 06/09/2010 Date of latest renewal: 24/04/2015 
Datum prve odobritve: 06/09/2010 Datum zadnjega podaljšanja: 24/04/2015
Not known (frequency cannot be estimated from the available data) 
Neznana pogostnost (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov)
• if you are pregnant, think you are pregnant or planning to have a baby. 
• če ste noseči, menite, da bi lahko bili noseči, ali načrtujete zanositev.
They don't usually need any treatment. 
Običajno jih ni treba zdraviti.
Adverse reactions occurred in approximately 80% of patients. 
Neželeni učinki so se pojavili pri približno 80% bolnikov.
The half-life of this initial phase is approximately 2 to 4 minutes. 
Razpolovna doba te začetne faze je približno 2 do 4 minute.
More serious side effects include: 
Resnejši neželeni učinki vključujejo:
For the measurement of FFR, five independent studies have been conducted. 
Za merjenje FFR so izvedli pet neodvisnih študij.
The data are insufficient to conclude about the risk of interactions at the level of these transporters given that a single concentration was evaluated in most instances. 
Toda podatkov ni dovolj, da bi se lahko sklepalo o tveganju za interakcije na ravni teh prenašalcev, glede na to, da so v večini primerov ocenjevali samo eno kocentracijo.
Effect of caffeine 
Učinek kofeina
Tell your doctor straight away if you think you are having severe side effects. 
Zdravniku takoj povejte, če menite, da imate hude neželene učinke.
However, given the proposed duration of use, the effects of the drug transporters are unlikely to be clinically relevant. 
Vendar pa zaradi predlaganega trajanja uporabe učinki prenašalcev zdravil verjetno ne bodo klinično pomembni.
• ringing in the ears 
• zvonjenje v ušesih
Patients initiated exercise using a standard or modified Bruce protocol. 
Bolniki so začeli s telesno vadbo z uporabo standardnega ali modificiranega Bruce-ovega protokola.
The doctor, nurse or medical technician will let you know when you can stand up. 
Zdravnik, medicinska sestra ali medicinski tehnik vam bo povedal/-a, kdaj lahko vstanete.
The median time between scans was 7 days (range of 1-104 days). 
Mediani čas med slikanji je bil 7 dni (razpon 1-104 dni).
Regadenoson should not be used during pregnancy unless clearly necessary. 
Regadenozona ne smete uporabljati pri nosečnicah, razen če je to jasno potrebno.
Stolker et al. 2015 (n=149) van Nunen et al. 2015 (n=98) 
Stolker in sodelavci 2015 (n=194) van Nunen in sodelavci 2015 (n = 98)
Dyspnoea did not correlate with a decrease in FEV1. 
Dispneja ni korelirala z zmanjšanjem FEV1.
Distribution Regadenoson is moderately bound to human plasma proteins (25-30%). 
Porazdelitev Regadenozon se zmerno veže na beljakovine človeške plazme (25-30%).
C-radiolabeled regadenoson to rats and dogs, most radioactivity (85-96%) was excreted in the form of unchanged regadenoson. 
C-označenega regadenozona podganam in psom se je večina radioaktivnosti (85-96%) izločila v obliki nespremenjenega regadenozona.
• changes in heart tracing tests (electrocardiogram) 
• spremembe preiskav sledenja srca (elektrokardiogram)
Children and adolescents Rapiscan should not be used in children and adolescents below the age of 18 years. 
Otroci in mladostniki Zdravilo Rapiscan se ne sme uporabljati pri otrocih in mladostnikih, starih manj kot 18 let.
Do not drive or operate machinery until these effects have improved. 
Ne vozite avtomobila in ne upravljajte s stroji, dokler ti učinki ne izzvenijo.
Adenosine was treated as a gold standard to estimate sensitivity, specificity, and the proportion of accuracy. 
Adenozin je predstavljal zlati standard za oceno občutljivosti, specifičnosti in razmerja natančnosti.
If any of these apply to you, tell your doctor before you are given the injection. 
Če kar koli od naštetega velja za vas, to povejte zdravniku, preden vam da injekcijo.
Rate Difference (regadenoson - Adenosine) (± 95% Confidence Interval 
Stopnja razlike (regadenozon - adenozin) (± SE) 95% interval zaupanja
• excessive sweating 
• pretirano znojenje
Harmful effects have been seen in animal studies but it is not known if there is a risk to humans. 
Pri študijah na živalih so opazili škodljive učinke, vendar tveganja za človeka niso znana.
They normally start soon after the Rapiscan injection and are usually over within 30 minutes. 
Običajno se začnejo kmalu po injiciranju zdravila Rapiscan in običajno izzvenijo v 30 minutah.
The side effects are usually mild. 
Neželeni učinki so običajno blagi.
During the exercise, a small amount of radiopharmaceutical is injected into the body, often into a vein in the hand. 
Med vadbo se v telo vbrizga majhna količina radiofarmacevtskega izdelka, pogosto v veno na roki.
Most increases resolved within 10 to 15 minutes, but in some cases, increases were observed at 45 minutes following administration. 
Povišanja so večinoma izginila v 10 do 15 minutah, vendar so v nekaterih primerih opazili povišanje 45 minut po uporabi zdravila.
• if you have asthma or lung disease. 
• ali imate astmo ali bolezen pljuč.
This leaflet was last revised in MM/YYYY 
Navodilo je bilo nazadnje revidirano dne MM/LLLL
Images are then taken of the heart. 
Zatem se naredijo posnetki srca.
It is not known whether Rapiscan can pass into breast milk and will only be given to you if your doctor thinks it is necessary. 
Ni znano, ali zdravilo Rapiscan prehaja v materino mleko, zato ga boste prejeli le, če zdravnik oceni, da je to potrebno.
The healthcare professionals will be responsible for the storage and disposal of this medicinal product. 
Za shranjevanje in odstranjevanje tega zdravila je odgovorno zdravstveno osebje.
This belongs to a group of medicines called ‘coronary vasodilators'. 
Slednja sodi v skupino zdravil, imenovanih "koronarni vazodilatatorji".
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10) uncommon (≥ 1/1,000 to < 1/100) and rare (≥ 1/10,000 to < 1/1,000). 
Pogostnosti so opredeljene kot zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100) in redki (≥ 1/10.000 do < 1/1.000).
• if you have low blood pressure (hypotension). 
• če imate nizek krvni tlak (hipotenzijo),
Safety and tolerability of repeated use of this product within 24 hours has not been characterised. 
Varnost in prenašanje pri ponavljajoči se uporabi zdravila v roku 24 ur nista bili opisani.
Rapiscan with food and drink 
Zdravilo Rapiscan skupaj s hrano in pijačo
The risk of significant increases in blood pressure may be higher in patients with uncontrolled hypertension. 
Tveganje pomembnega povišanja krvnega tlaka je lahko večje pri bolnikih z nenadzorovano hipertenzijo.
It may cause other symptoms (headache or shortness of breath) that could affect your ability to drive or use machinery. 
Povzroči lahko tudi druge simptome (glavobol ali kratko sapo), ki lahko vplivajo na vašo sposobnost vožnje ali upravljanja s stroji.
All 1404 patients initially had a baseline MPI scan at rest in accordance with ASNC 2009 guidelines. 
Vsem 1404 bolnikom so na začetku izvedli izhodiščno MPI slikanje v mirovanju v skladu s smernicami ASNC 2009.
Respiratory effects 
Respiratorni učinki
Measurement of FFR 
Merjenje FFR
• anxiety, difficulty sleeping 
• anksioznost, težave s spanjem
Comparison of the images obtained with regadenoson to those obtained with adenosine was performed as follows. 
Primerjava posnetkov, pridobljenih z uporabo regadenozona, s tistimi, pri katerih je bil uporabljen adenozin, je bila opravljena na naslednji način.
An intermediate phase follows, with a half-life on average of 30 minutes coinciding with loss of the pharmacodynamic effect. 
Sledi vmesna faza s povprečno razpolovno dobo 30 minut, ki sovpada s pojenjanjem farmakodinamičnega učinka.
The use of bronchodilator therapy for symptoms was not different between regadenoson and placebo. 
Uporaba zdravljenja simptomov z bronhodilatatorjem se ni razlikovala med regadenozonom in placebom.
The regadenoson plasma concentration-time profile in healthy volunteers is multi-exponential in nature and best characterised by 3-compartment model. 
Profil plazemske koncentracije regadenozona v odvisnosti od časa pri zdravih prostovoljcih je multi-eksponencialen po svoji naravi in ga najbolje označuje 3-razdelčni model.
Heart rate returns to baseline within 10 minutes. 
Srčni utrip se vrne na izhodiščnega v 10 minutah.
Subsequentially, patients from both groups, returned 1-14 days later, to undergo a second stress MPI regadenoson study without exercise. 
V nadaljevanju so se bolniki iz obeh skupin vrnili 1-14 dni kasneje, da bi opravili drugo stresno študijo MPI z regadenozonom brez telesne vadbe.
The terminal phase consists of a decline in plasma concentration with a half-life of approximately 2 hours. 
Končno fazo sestavlja upad koncentracij v plazmi s približno 2-urno razpolovno dobo.
The safety and efficacy of regadenoson in children below the age of 18 years have not yet been established. 
Varnost in učinkovitost regadenozona pri otrocih, starih do 18 let, še nista bili dokazani.
Repeat dosing within 10 minutes - except in patients where the duration of hyperaemia lasted for more than 10 minutes - caused a similar effect on peak and duration of maximum hyperaemia. 
Ponovna uporaba v 10 minutah - razen pri bolnikih, pri katerih je hiperemija trajala več kot 10 minut - je, kar zadeva največjo izraženost in trajanje najizrazitejše hiperemije, privedla do podobnega učinka.
The disposition of regadenoson was studied in 18 subjects with various degrees of renal function and in 6 healthy subjects. 
Razporeditev regadenozona so preučili pri 18 osebah z različnimi stopnjami okvare ledvic in pri 6 zdravih osebah.
• if you have high blood pressure that is not controlled, especially if this has been accompanied by recent episodes of nose bleed, headache or blurred or double vision. 
• če imate visok krvni tlak, ki ni pod nadzorom, zlasti v povezavi z nedavnimi epizodami krvavitev iz nosu, glavobolov ali zamegljenega ali dvojnega vida,
Classification agreement Cohen's kappa 
Klasifikacijsko ujemanje Cohenov kappa koeficient
Pregnancy and breast-feeding Before you are given Rapiscan, tell your doctor: 
Nosečnost in dojenje Preden prejmete zdravilo Rapiscan, povejte svojemu zdravniku:
Particular care should be taken with the following medicines: 
Pri uporabi naslednjih zdravil je potrebna posebna previdnost:
This leaflet is available in all EU/EEA languages on the European Medicines Agency website. 
To navodilo za uporabo je na voljo v vseh uradnih jezikih EU/EGP na spletni strani Evropske agencije za zdravila
However, the maximum observed plasma concentrations as well as volumes of distribution estimates were similar across the groups. 
Vendar pa so bili največje opažene koncentracije v plazmi in ocenjeni volumni porazdelitve v vseh skupinah podobni.
• discomfort in the bones and muscles 
• nelagodje v kosteh in mišicah
Patients who did not achieve ≥ 85% maximum predicted heart rate (MPHR) and/or ≥ 5 METS (metabolic equivalents), transitioned into a 3-5 minutes walking recovery where during the first 3 minutes of recovery, patients were randomized 1:1. 
Bolniki, ki niso dosegli ≥ 85 % največjega predvidenega utripa srca (MPHR-maximum predicted heart rate) in/ali ≥ 5 MET (presnovnih ekvivalentov), so prešli v 3-5 minutno okrevanje s hojo, kjer so bolnike v prvih 3 minutah okrevanja randomizirali v razmerju 1:1.
• if you have any heart or blood vessel condition, particularly one that gets worse when your blood pressure decreases. 
• ali imate bolezni srca ali žil, zlasti take, ki se ob zmanjšanju krvnega tlaka poslabšajo.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch. 
V natisnjenem navodilu za uporabo zdravila morata biti navedena ime in naslov izdelovalca, odgovornega za sprostitev zadevne serije
The pharmacokinetic parameters of regadenoson have not yet been studied in the paediatric population (< 18 years). 
Pediatrična populacija Farmakokinetičnih parametrov regadenozona do sedaj niso preučili pri pediatrični populaciji (< 18 let).
Mean APV increased to greater than twice baseline by 30 seconds and decreased to less than half of the maximal effect within 10 minutes (see section 5.2). 
Povprečna hitrost vrha se je povzpela na več kot dvakratno izhodiščno vrednost v 30 sekundah in se je zmanjšala za manj kot polovico največjega učinka v 10 minutah (glejte poglavje 5.2).
For further information, please refer to the complete Summary of Product Characteristics. 
Za nadaljnje informacije glejte celoten Povzetek glavnih značilnosti zdravila.
Regadenoson causes a rapid increase in heart rate (see sections 4.4 and 5.1). 
Regadenozon povzroči hitro zvišanje srčnega utripa (glejte poglavji 4.4 in 5.1).
The images from MPI 1 and MPI 2 were compared for presence or absence of perfusion defects. 
Slike iz MPI 1 in MPI 2 so primerjali glede prisotnosti ali odsotnosti napak v perfuziji.
Age, gender, and race have minimal effects on the pharmacokinetics of regadenoson. 
Starost, spol in rasa imajo minimalne učinke na farmakokinetiko regadenozona.
The incidence of a FEV1 reduction > 15% from baseline after regadenoson administration was assessed in three randomised, controlled clinical studies. 
Incidenca zmanjšanja FEV1 > 15% od izhodišča po dajanju regadenozona je bila ocenjena v treh randomiziranih, nadziranih kliničnih študijah.
Consideration should be given to delaying regadenoson administration until blood pressure is well controlled 
Treba je razmisliti o odložitvi uporabe regadenozona, dokler krvni tlak ni dobro nadzorovan.
Read all of this leaflet carefully before you are given this medicine because it contains important information for you. 
Preden dobite zdravilo, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
A total of 1,871 of these patients had images considered valid for the primary efficacy evaluation, including 1,294 (69%) men and 577 (31%) women with a median age of 66 years (range 26-93 years of age). 
Pri skupno 1.871 od teh bolnikov so bili posnetki ocenjeni kot veljavni za ocenitev primarne učinkovitosti, vključno s 1.294 (69%) moških in 577 (31%) žensk z mediano starostjo 66 let (razpon starosti 26-93 let).
Your doctor may then give you an injection of a medicine called aminophylline that reduces these effects. 
Zdravnik vam lahko da injekcijo zdravila, ki se imenuje aminofilin, ki te učinke ublaži.
A relationship between increased severity of disease and the increased incidence of dyspnoea was apparent in patients with asthma, but not in patients with COPD. 
Razmerje med povečano resnostjo bolezni in povečano incidenco dispneje je bilo opazno pri bolnikih z astmo, ne pa pri bolnikih s KOPB.
Assessment of adverse reactions for regadenoson is based on safety data from clinical studies and postmarketing experience. 
Ocena neželenih učinkov regadenozona temelji na podatkih varnosti, pridobljenih v kliničnih študijah in iz izkušenj v obdobju trženja.
The same applies to the FFR measurement where the maximal myocardial blood flow is decreased in presence of severe coronary artery stenosis. 
Enako velja za meritev FFR, kjer je maksimalni krvni pretok v miokardu zmanjšan, kadar je prisotna huda stenoza koronarnih arterij.
Headache was reported by 27% of subjects who received regadenoson in clinical trials. 
O glavobolu so poročali pri 27% osebah, ki so v kliničnih preskušanjih prejele regadenozon.
If your doctor thinks that you are having severe side effects, or the effects of Rapiscan are lasting too long, they may give you an injection of a medicine called aminophylline that reduces these effects. 
Če vaš zdravnik meni, da imate hude neželene učinke ali če učinki zdravila Rapiscan trajajo predolgo, boste morda prejeli injekcijo zdravila, ki se imenuje aminofilin, ki te učinke ublaži.
Rapiscan is injected by a healthcare professional (a doctor, nurse or medical technician) in a medical facility where your heart and blood pressure can be monitored. 
Zdravilo Rapiscan vam injicira zdravstveno osebje (zdravnik, medicinska sestra ali medicinski tehnik) v zdravstveni ustanovi, kjer lahko nadzirajo vaše srce in krvni tlak.
What Rapiscan is and what it is used for 
Kaj je zdravilo Rapiscan in za kaj ga uporabljamo
The excretion of regadenoson in milk has not been studied in animals. 
Izločanja regadenozona v mleko pri živalih niso preučili.
All adverse reactions are presented in the table below and are listed by system organ class and frequency. 
Vsi neželeni učinki, predstavljeni v spodnji tabeli, so razvrščeni po organskih sistemih in pogostnosti.
In the pooled study population, 68% of patients had 0-1 segments showing reversible defects on the initial scan, 24% had 2-4 segments, and 9% had ≥ 5 segments. 
V združeni populaciji študije je imelo 68% bolnikov 0-1 segment, ki so kazali reverzibilne okvare na začetnem slikanju, 24% jih je imelo 2-4 segmente in 9% jih je imelo ≥ 5 segmentov.
Within the dose range of 0.003-0.02 mg/kg (or approximately 0.18-1.2 mg) in healthy subjects, clearance, terminal half-life or volume of distribution do not appear dependent upon the dose. 
V razponu odmerka 0,003-0,02 mg/kg (ali približno 0,181,2 mg) pri zdravih osebah očistek, končna razpolovna doba ali volumen porazdelitve niso odvisni od odmerka.
• difficulty in breathing (bronchospasm) 
• oteženo dihanje (bronhospazem)
(n = 1,871) 
Kombinirani študiji (n = 1.871)
Dipyridamole increases blood adenosine levels and the response to regadenoson may be altered when blood adenosine levels are increased. 
Dipiridamol zvišuje ravni adenozina v krvi in odziv na regadenozon se lahko spremeni z zvišanjem ravni adenozina v krvi.
Regadenoson does not significantly inhibit the transporters OAT1, OAT3, OCT1, OATP1B1, OATP1B3, MATE1, MATE2-K, BCRP, P-gp, BSEP, ENT 1 or ENT2 at 1 µM. 
Regadenozon ne zavira pomembno prenašalcev OAT1, OAT3, OCT1, OATP1B1, OATP1B3, MATE1, MATE2-K, BCRP, P-gp, BSEP, ENT 1 ali ENT2 pri koncentraciji 1 µM.
The radiopharmaceutical may be injected directly into the same catheter as Rapiscan. 
Radiofarmacevtski izdelek se lahko injicira neposredno v isti kateter kot zdravilo Rapiscan.
Greater than 55% of the regadenoson dose is excreted unchanged in the urine and factors that decrease clearance do not affect the plasma concentration in the early stages after dosing when clinically meaningful pharmacologic effects are observed. 
Več kot 55% odmerka regadenozona se nespremenjenega izloči v urinu in dejavniki, ki vplivajo na zmanjšanje očistka, ne vplivajo na koncentracije v plazmi v zgodnjih fazah po odmerjanju, ko so opazili klinično pomembne farmakološke učinke.
Contents of the pack and further information 
Vsebina pakiranja in dodatne informacije
Very common Electrocardiogram ST segment changes Common 
Zelo pogosti spremembe segmentov ST v elektrokardiogramu
Animal studies on pre- and post-natal development have not been conducted. 
Študij na živalih glede prenatalnega in postnatalnega razvoja niso izvedli.
• Second or third degree atrioventricular (AV) block or sinus node dysfunction, unless these patients have a functioning artificial pacemaker. 
• disfunkcija atrioventrikularnega (AV) bloka ali sinusnega vozla druge ali tretje stopnje, razen če imajo bolniki delujoč umetni spodbujevalnik,
Therefore, regadenoson would be expected to have no or negligible influence on the ability to drive or use machines once treatment has been completed and these reactions have resolved. 
Zato se pričakuje, da regadenozon nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje ali upravljanja s stroji po zaključku zdravljenja ali izzvenetju teh učinkov.
If you have any further questions, ask your doctor or pharmacist. 
• Če imate dodatna vprašanja, se posvetujte z zdravnikom ali farmacevtom.
Millmount Healthcare Limited, Block 7, City North Business Campus, Stamullen, Co Meath, K32 YD60 Ireland 
Millmount Healthcare Limited, Block 7, City North Business Campus, Stamullen, Co Meath, K32 YD60, Irska
Your heart rate and blood pressure will be monitored. 
Vaš srčni utrip in krvni tlak bodo nadzirali.
The baseline MPI scans at rest and those without exercise at 1-14 days later from both groups, constituted the MPI 2 phase. 
Izhodiščna slikanja MPI v mirovanju in tista brez vadbe v času 1-14 dni kasneje iz obeh skupin predstavljajo fazo MPI 2.
• high blood pressure, paleness, cold extremities 
• visok krvni tlak, bledica, hladne okončine
Adverse reactions in most patients receiving regadenoson in clinical trials were mild, transient (usually resolving within 30 minutes after receiving regadenoson) and required no medical intervention. 
Neželeni učinki pri večini bolnikov, ki so prejeli regadenozon v kliničnih študijah, so bili blagi, prehodni (običajno so izzveneli v 30 minutah po prejemu regadenozona) in niso zahtevali medicinskega poseganja.
In the measurement of FFR, the time to peak maximum hyperaemia was 30±13 seconds. 
Pri merjenju FFR je čas, po katerem je prišlo do najizrazitejše hiperemije, znašal 30 ± 13 sekund.
Also, there was no apparent effect of 200 mg or 400 mg of caffeine on regadenoson plasma concentrations. 
Poleg tega ni bilo opaznih vplivov 200 mg ali 400 mg kofeina na plazemske koncentracije regadenozona.